Phase II data shows Sorafenib to demonstrate efficacy in advanced thyroid cancer « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Phase II data shows Sorafenib to demonstrate efficacy in advanced thyroid cancer

Posted on June 9, 2008 by crimsoncanary

Phase II data show sorafenib to demonstrate efficacy in patients with advanced thyroid carcinoma. The overall clinical benefit rate (partial response + stable disease)was 77% and the drug had an acceptable safetyprofile.

Filed under: kinase | Tagged: bayer, multikinase, Nexavar, onyx, PDGFR, phase iii, raf, RET, sorafenib, VEGFR

« CytRx to Acquire Innovive Pharmaceuticals Phase III Dasatinib data demonstrates efficacy in Imatinib Resistant CML »